Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RTTR

Ritter Pharmaceuticals (RTTR) Stock Price, News & Analysis

Ritter Pharmaceuticals logo

About Ritter Pharmaceuticals Stock (NASDAQ:RTTR)

Advanced Chart

Key Stats

Today's Range
$3.25
$3.65
50-Day Range
$0.45
$4.09
52-Week Range
$0.15
$1.27
Volume
29,326 shs
Average Volume
14.23 million shs
Market Capitalization
$160.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.

Receive RTTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ritter Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RTTR Stock News Headlines

Dr. John D. Ritter
From Social Security to Social Prosperity?
In less than a decade, Social Security could be out of money. But a surprising plan from Trump’s inner circle may not just save the system — it could unlock a major opportunity for savvy investors. Financial insider Jim Rickards calls it “Social Prosperity,” and says those who act now could see the biggest gains.
Kristen Ritter
Dr. Harold K. Ritter
See More Headlines

RTTR Stock Analysis - Frequently Asked Questions

Ritter Pharmaceuticals Inc (NASDAQ:RTTR) released its quarterly earnings results on Friday, May, 1st. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.01.

Ritter Pharmaceuticals's stock reverse split before market open on Friday, March 23rd 2018. The 1-10 reverse split was announced on Thursday, March 22nd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 22nd 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Ritter Pharmaceuticals (RTTR) raised $20 million in an initial public offering (IPO) on Wednesday, June 24th 2015. The company issued 4,000,000 shares at $5.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO and Barrington Research was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ritter Pharmaceuticals investors own include Endologix (ELGX), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), APA (APA), Charles Schwab (SCHW), Genocea Biosciences (GNCA) and Hudson Technologies (HDSN).

Company Calendar

Last Earnings
5/01/2020
Today
4/27/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RTTR
Fax
N/A
Employees
7
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,130,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.10 per share
Price / Book
34.75

Miscellaneous

Free Float
N/A
Market Cap
$160.38 million
Optionable
Not Optionable
Beta
-0.43
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:RTTR) was last updated on 4/28/2025 by MarketBeat.com Staff
From Our Partners